Form 4: GeneDx CFO Sells Shares for Tax Obligations

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the vesting of restricted stock units and subsequent sale of shares to cover tax withholding obligations.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), reported transactions involving the company's Class A Common Stock.
• On March 15, 2026, 3,815 restricted stock units (RSUs) vested, converting into Class A Common Stock.
• On March 16, 2026, an additional 7,197 RSUs vested, converting into Class A Common Stock.
• Concurrently on March 16, 2026, Feeley sold a total of 5,706 shares of Class A Common Stock in multiple transactions to satisfy tax withholding obligations related to the RSU vesting.
• The sales occurred at weighted average prices ranging from $75.735 to $78.16 per share.
• Following these reported transactions, Feeley beneficially owns 27,148 shares of Class A Common Stock directly.
• Additionally, Feeley holds contingent rights to receive up to an aggregate of 109,423 shares from RSUs and options to purchase up to an aggregate of 25,906 shares of Class A Common Stock, which vest according to their respective terms.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While it involves a reduction in direct share ownership, it's a non-discretionary sale for tax purposes, which is a common occurrence for executives receiving equity compensation.

Positives

• The vesting of restricted stock units represents a form of equity compensation for the Chief Financial Officer, indicating continued service and alignment of interests with shareholders.

Negatives

• The sale of 5,706 shares, even for tax purposes, results in a reduction of the Chief Financial Officer's direct equity stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and non-discretionary event for executives receiving equity compensation, particularly in the biotechnology and diagnostics industry where equity incentives are a significant part of compensation packages. These sales are generally not indicative of a change in management's outlook on the company's prospects but rather a standard tax planning mechanism.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine tax-related sales, not a discretionary divestment. The CFO still retains significant equity exposure through remaining shares, RSUs, and options.
• Employees: No direct impact.

Key Dates

Recommendation

The filing details routine insider transactions related to equity compensation and tax obligations. These 'sell to cover' sales are non-discretionary and do not reflect a change in the insider's investment sentiment or the company's fundamentals. Therefore, the filing itself does not provide a basis for a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this information.

Keywords

GeneDx Holdings Corp., WGS, Kevin Feeley, CFO, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Beneficial Ownership